HC Wainwright Begins Coverage on Bausch + Lomb (NYSE:BLCO)
HC Wainwright Begins Coverage on Bausch + Lomb (NYSE:BLCO)
HC Wainwright started coverage on shares of $Bausch + Lomb Corp. (BLCO.US)$ in a report released on Monday, MarketBeat.com reports. The brokerage issued a buy rating and a $21.00 price target on the stock.
HC Wainwright開始報道以下股票$博士倫 (BLCO.US)$在週一發佈的一份報告中，MarketBeat.com報道。該經紀公司對該股發佈了買入評級和21.00美元的目標價。
Other research analysts have also issued reports about the stock. Evercore ISI began coverage on shares of Bausch + Lomb in a report on Friday, June 24th. They issued an outperform rating and a $21.00 target price for the company. Bank of America began coverage on Bausch + Lomb in a report on Tuesday, May 31st. They issued a buy rating for the company. The Goldman Sachs Group reissued a neutral rating and set a $19.00 target price (down previously from $22.00) on shares of Bausch + Lomb in a research note on Tuesday, August 30th. JPMorgan Chase & Co. began coverage on Bausch + Lomb in a research note on Tuesday, May 31st. They set a neutral rating and a $20.00 price target on the stock. Finally, Guggenheim initiated coverage on Bausch + Lomb in a report on Tuesday, May 31st. They issued a buy rating and a $24.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Bausch + Lomb has a consensus rating of Moderate Buy and an average target price of $23.23.
其他研究分析師也發佈了有關該股的報告。Evercore ISI在6月24日星期五的一份報告中開始報道博士倫的股票。他們對該公司發佈了跑贏大盤的評級和21.00美元的目標價。美國銀行在5月31日(星期二)的一份報告中開始對博士倫進行報道。他們對該公司的評級為買入。8月30日，週二，高盛在一份研究報告中重新發布了博士倫的中性評級，並將博士倫的目標價從此前的22.00美元下調至19.00美元。摩根大通公司在5月31日星期二的一份研究報告中開始對博士倫進行報道。他們為該股設定了中性評級和20.00美元的目標價。最後，古根海姆在5月31日星期二的一份報告中發起了對博士倫的報道。他們為該公司發佈了買入評級和24.00美元的目標價。4名股票研究分析師對該股的評級為持有，10名分析師給予該公司買入評級。根據MarketBeat.com的數據，博士倫的普遍評級為中等買入，平均目標價為23.23美元。
Get Bausch + Lomb alerts:
到達博施+倫布警報：
Bausch + Lomb Trading Up 0.5 %
博士倫股價上漲0.5%
NYSE:BLCO opened at $17.13 on Monday. The firm's fifty day moving average price is $15.73. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.57 and a quick ratio of 1.10. Bausch + Lomb has a 52 week low of $12.20 and a 52 week high of $20.20.
紐約證券交易所：BLCO週一開盤報17.13美元。該公司的50日移動均線價格為15.73美元。該公司的債務權益比為0.35，流動比率為1.57，速動比率為1.10。博士倫的52周低點為12.20美元，52周高點為20.20美元。
Hedge Funds Weigh In On Bausch + Lomb
對衝基金看好博士倫
A number of hedge funds have recently modified their holdings of BLCO. UBS Asset Management Americas Inc. purchased a new position in shares of Bausch + Lomb in the 2nd quarter valued at approximately $66,656,000. Icahn Carl C bought a new position in Bausch + Lomb in the 2nd quarter worth approximately $53,340,000. Eminence Capital LP bought a new position in Bausch + Lomb during the 2nd quarter valued at $42,487,000. Laurion Capital Management LP bought a new stake in shares of Bausch + Lomb during the 2nd quarter worth $16,154,000. Finally, Segantii Capital Management Ltd bought a new stake in shares of Bausch + Lomb during the 2nd quarter worth $11,659,000. 10.32% of the stock is currently owned by hedge funds and other institutional investors.
多家對衝基金最近調整了對BLCO的持股。瑞銀資產管理美洲公司在第二季度購買了博士倫新的股票頭寸，價值約66,656,000美元。伊坎·卡爾·C在第二季度購買了博士倫的新頭寸，價值約53,340,000美元。Eminence Capital LP在第二季度購買了博士倫的新頭寸，價值42,487,000美元。Laurion Capital Management LP在第二季度購買了博士倫價值16,154,000美元的新股。最後，Segantii Capital Management Ltd在第二季度購買了博士倫價值11,659,000美元的新股。10.32%的股票目前由對衝基金和其他機構投資者持有。
Bausch + Lomb Company Profile
博士倫公司簡介
(Get Rating)
(獲取評級)
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.
博士倫公司是一家全球性的眼科保健公司。它通過三個部門運作：視力保健/消費者保健、眼科製藥和外科。視力護理/消費者保健細分市場提供涵蓋各種佩戴方式的隱形眼鏡，包括日常一次性和經常更換的隱形眼鏡；以及針對眼睛過敏、結膜炎和乾眼等各種疾病的隱形眼鏡護理產品、非處方眼藥水、眼部維生素和礦物質補充劑。
譯文內容由第三人軟體翻譯。